BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion
Sponsors
Karolinska University Hospital, Princess Maxima Center For Pediatric Oncology, Fondazione Gimema Franco Mandelli Onlus, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, Ospedale Pediatrico Bambino Gesu
Conditions
Acute Lymphoblastic LeukaemiaAcute lymphoblastic leukemiaAdult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.Framework for OptimizingPrecursor B-acute lymphoblastic leukemiaRefiningand Unifying Management of HSCT in Pediatric ALL
Phase 2
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
RecruitingCTIS2022-501050-11-01
Start: 2020-07-13Target: 5943Updated: 2025-12-17
HOVON 146 ALL: Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. A phase II trial.
Active, not recruitingCTIS2024-511050-44-00
Start: 2018-05-16Target: 71Updated: 2024-11-20
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
RecruitingCTIS2025-522052-13-00
Start: 2025-12-24Target: 735Updated: 2025-11-24
Phase 3
Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
SuspendedCTIS2022-502503-30-00
Start: 2022-12-15Target: 206Updated: 2026-01-27
Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. ALL2820
Active, not recruitingCTIS2023-508968-30-00
Start: 2021-09-08Target: 236Updated: 2024-10-01